Research Project

Project Title:	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger. ALXN1210-TMA-315
Project Type:	Clinical Trial, Enrolment ongoing
Disease group(s):	Thrombotic microangiopathies
Project Summary:	This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.
Lead principal investigator(s):	Piero Ruggenenti, Bergamo
Co-investigator(s):	Laura Cappelletti, Bergamo
Project Period:	07/2021 - 06/2024
ClinicalTrials.gov:	NCT04743804